AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3734514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3734514 — intervention group
Group type: EXPERIMENTAL
Intervention: Raynaud's patients
Number of subjects: 39
Study 30355360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath emollients plus standard eczema care
Number of subjects: 482
Study 30355360 — intervention group
Group type: COMPARATOR
Intervention: Standard eczema care only
Number of subjects: 482
Study 27058908 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 8966
Study 27058908 — intervention group
Group type: COMPARATOR
Intervention: Stress Testing
Number of subjects: 8966
Study 23995830 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Efficacy Scale (SES)
Number of subjects: 47
Study 23212500 — intervention group
Group type: EXPERIMENTAL
Intervention: Good trainee performances
Number of subjects: 41
Study 23212500 — intervention group
Group type: COMPARATOR
Intervention: Poor trainee performances
Number of subjects: 41
Study 20216274 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 100
Study 20216274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18657672 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d for 3 days before surgery
Number of subjects: 124
Study 18657672 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 124
Study 18657672 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher postoperative peak N-terminus pro-B-type natriuretic peptide levels
Number of subjects: 124
Study 15940775 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise program with strength training and lifestyle advice
Number of subjects: 109
Study 15940775 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 109
Study 13678426 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management of anticoagulation with near patient INR testing monitor, test strips, and quality control material for home testing, after attending at least two training sessions.
Number of subjects: 49
Study 13678426 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group) attending hospital or practice based anticoagulant clinics.
Number of subjects: 49
Study 12687426 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a supra‐aponeurotic polypropylene mesh in the primary closure of laparotomies (50 patients)
Number of subjects: 100
Study 12687426 — intervention group
Group type: COMPARATOR
Intervention: Standard closure without mesh (50 patients)
Number of subjects: 100
Study 9794661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 390
Study 9794661 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser vaporization
Number of subjects: 390
Study 9794661 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision
Number of subjects: 390
Study 9794661 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 390
Study 7697849 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ICD implantation (n = 29)
Number of subjects: 60
Study 7697849 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (n = 31)
Number of subjects: 60
Study 2504629 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepartricin 150,000 IU/day for 30 days
Number of subjects: 38
Study 2504629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7585 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 38
Study 7585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31476522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue stretching exercises (TSE), performed five times a week for four weeks, consisting of dynamic and static passive stretching exercises (20 repetitions each)
Number of subjects: 25
Study 31476522 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 25
Study 28692630 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (n = 10; 7 females, 3 males)
Number of subjects: 21
Study 28692630 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11; 2 females, 9 males)
Number of subjects: 21
Study 25712312 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily
Number of subjects: 500
Study 24277815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone binding globulin
Number of subjects: 643
Study 24277815 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (in early group)
Number of subjects: 643
Study 24277815 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous sex steroid levels
Number of subjects: 643
Study 24277815 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone concentrations
Number of subjects: 643
Study 24277815 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal proximity to menopause
Number of subjects: 643
Study 21755316 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester mesh
Number of subjects: 78
Study 21755316 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene mesh
Number of subjects: 78
Study 19565542 — intervention group
Group type: EXPERIMENTAL
Intervention: T-614 50 mg/day for 24 weeks
Number of subjects: 489
Study 19565542 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 10 mg/week for 4 weeks and 15 mg/week for 20 weeks
Number of subjects: 489
Study 19565542 — intervention group
Group type: EXPERIMENTAL
Intervention: T-614 25 mg/day for 4 weeks and 50 mg/day for 20 weeks
Number of subjects: 489
Study 19565542 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (T-614 and MTX)
Number of subjects: 489
Study 19565542 — intervention group
Group type: EXPERIMENTAL
Intervention: T-614 therapy groups
Number of subjects: 489
Study 16397282 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (various intravenous doses)
Number of subjects: 0
Study 15037526 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg BID)
Number of subjects: 9
Study 15037526 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (100 mg/d)
Number of subjects: 9
Study 11109976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraception (ethinylestradiol plus desogestrel) for 21 days each month for 12 months
Number of subjects: 43
Study 11109976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraception (ethinylestradiol plus desogestrel) plus spironolactone daily for 12 months
Number of subjects: 43
Study 11109976 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 43
Study 9079166 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic adhesive athletic tape
Number of subjects: 20
Study 9079166 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adhesive prewrap (underwrap)
Number of subjects: 20
Study 9079166 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 minutes of vigorous exercise
Number of subjects: 20
Study 9079166 — intervention group
Group type: COMPARATOR
Intervention: No external ankle support
Number of subjects: 20
Study 8371916 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 (0.006% concentration, 60 micrograms/ml) administered once daily
Number of subjects: 50
Study 8371916 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 (0.006% concentration, 60 micrograms/ml) administered twice daily
Number of subjects: 50
Study 8371916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8371916 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 (both dosing regimens)
Number of subjects: 50
Study 29445188 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment (night shifts)
Number of subjects: 0
Study 29445188 — intervention group
Group type: COMPARATOR
Intervention: Circadian alignment (day shifts)
Number of subjects: 0
Study 29445188 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 0
Study 26562929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 10
Study 26562929 — intervention group
Group type: COMPARATOR
Intervention: Control (no hyperventilation)
Number of subjects: 10
Study 24736769 — intervention group
Group type: EXPERIMENTAL
Intervention: Midstance to Midstance Running (MMR)
Number of subjects: 18
Study 24736769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 18
Study 23044231 — intervention group
Group type: EXPERIMENTAL
Intervention: UC‐MSC transplantation
Number of subjects: 54
Study 20392866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone for 10 weeks
Number of subjects: 86
Study 20392866 — intervention group
Group type: COMPARATOR
Intervention: Metformin for 10 weeks
Number of subjects: 86
Study 18263770 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 18263770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0
Study 18263770 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 18263770 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 0
Study 15948994 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 972
Study 15948994 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid ointment regimen
Number of subjects: 972
Study 15948994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 972
Study 12868009 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g/day)
Number of subjects: 21
Study 12868009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10561192 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) alone
Number of subjects: 48
Study 10561192 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) alone
Number of subjects: 48
Study 10561192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential interleukin-3 (IL-3) and GM-CSF
Number of subjects: 48
Study 8696542 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 154
Study 8696542 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 154
Study 1908478 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG alone (Group II)
Number of subjects: 68
Study 1908478 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG plus GnRH agonists (Group III)
Number of subjects: 68
Study 1908478 — intervention group
Group type: COMPARATOR
Intervention: Normal cycles (Group I)
Number of subjects: 68
Study 6347316 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (HSV)
Number of subjects: 137
Study 6347316 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 137
Study 31473553 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in editorial leadership positions (Editor-in-chief/deputies, Associate/section editors)
Number of subjects: 8423
Study 31473553 — intervention group
Group type: COMPARATOR
Intervention: Men (M.D. psychiatrists)
Number of subjects: 8423
Study 31473553 — intervention group
Group type: COMPARATOR
Intervention: Women (Ph.D. psychologists)
Number of subjects: 8423
Study 31473553 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in editorial leadership positions
Number of subjects: 8423
Study 31473553 — intervention group
Group type: EXPERIMENTAL
Intervention: Editorial board positions
Number of subjects: 8423
Study 30118808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate (NaNO3) supplementation for eight weeks
Number of subjects: 21
Study 30118808 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 21
Study 26869087 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study 26869087 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA/EPA supplementation
Number of subjects: 0
Study 26869087 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron + DHA/EPA combination
Number of subjects: 0
Study 26869087 — intervention group
Group type: COMPARATOR
Intervention: Control (Iron alone)
Number of subjects: 0
Study 23111536 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term secondary prevention programme with one further rehabilitation session after 6 months and regular telephone reminders over 36 months
Number of subjects: 600
Study 23111536 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study 22286978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor formulation 1 (250 mg)
Number of subjects: 20
Study 22286978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor formulation 2 (250 mg)
Number of subjects: 20
Study 20418301 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (15 mg/kg preoperatively, 5 mg/kg 3 times per day for 5 days postoperatively)
Number of subjects: 59
Study 20418301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17554473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml paté
Number of subjects: 30
Study 17554473 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml egg white
Number of subjects: 30
Study 17554473 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml omelette
Number of subjects: 30
Study 17554473 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml radiolabeled omelette
Number of subjects: 30
Study 16096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Flock-of-Birds electromagnetic tracking system for asymptomatic subjects
Number of subjects: 60
Study 16096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Flock-of-Birds electromagnetic tracking system for symptomatic subjects
Number of subjects: 60
Study 12510544 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostanoids (including prostaglandin E1)
Number of subjects: 557
Study 12510544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study 12510544 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin and its analogues
Number of subjects: 557
Study 9834957 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow‐dissolving formulation
Number of subjects: 13
Study 9834957 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium‐dissolving formulation
Number of subjects: 13
Study 9834957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast‐dissolving formulation
Number of subjects: 13
Study 9834957 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderal 80 mg
Number of subjects: 13
Study 7657848 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 mg twice daily)
Number of subjects: 160
Study 7657848 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (2.5 mg twice daily)
Number of subjects: 160
Study 7657848 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 160
Study 7657848 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 160
Study 7657848 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine non-responders
Number of subjects: 160
Study 7657848 — intervention group
Group type: COMPARATOR
Intervention: Enalapril non-responders
Number of subjects: 160
Study 2750531 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 U/m2/week of GH by daily subcutaneous injections for a mean of 0.82 years
Number of subjects: 31
Study 2750531 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 U/m2/week of GH by daily subcutaneous injections for a mean of 0.92 years
Number of subjects: 31
Study 789083 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (adjusted every two weeks to maintain serum level between 0.7 and 1.0 mmol/1)
Number of subjects: 0
Study 789083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31691849 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 120
Study 31691849 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 120
Study 31691849 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 120
Study 31547761 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan interventions (depletion, loading, balanced)
Number of subjects: 611
Study 31547761 — intervention group
Group type: COMPARATOR
Intervention: 5-HTTLPR genotype
Number of subjects: 611
Study 28846009 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg omega‐3 fatty acids plus 400 mg vitamin E
Number of subjects: 56
Study 28846009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 26324672 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB therapy (telmisartan)
Number of subjects: 1228
Study 26324672 — intervention group
Group type: COMPARATOR
Intervention: Non-ARB standard therapy
Number of subjects: 1228
Study 25168268 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg tabalumab Q4W
Number of subjects: 182
Study 25168268 — intervention group
Group type: EXPERIMENTAL
Intervention: 60/120 mg tabalumab Q4W
Number of subjects: 182
Study 25168268 — intervention group
Group type: EXPERIMENTAL
Intervention: 60/120/60 mg tabalumab Q4W
Number of subjects: 182
Study 22361261 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily for 6 weeks)
Number of subjects: 32
Study 22361261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 20503799 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplified sound samples (mild gain, moderate gain)
Number of subjects: 48
Study 20503799 — intervention group
Group type: COMPARATOR
Intervention: Unamplified sound samples
Number of subjects: 48
Study 17213240 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive swallowing stimulation (duration of stimulation: 7.39±3.6 days)
Number of subjects: 33
Study 17213240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 33
Study 16288342 — intervention group
Group type: EXPERIMENTAL
Intervention: CP and iodoform
Number of subjects: 245
Study 16288342 — intervention group
Group type: COMPARATOR
Intervention: CP alone
Number of subjects: 245
Study 12356283 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.396 microg administered intravenously as a bolus injection)
Number of subjects: 8
Study 12356283 — intervention group
Group type: COMPARATOR
Intervention: Lithium treatment (period preceding the 6th study day)
Number of subjects: 8
Study 10197827 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate therapy
Number of subjects: 34
Study 7758212 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 0
Study 7758212 — intervention group
Group type: COMPARATOR
Intervention: CAPD patients
Number of subjects: 0
Study 7758212 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 0
Study 2317466 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention in pregnancy in addition to standard antenatal care
Number of subjects: 509
Study 2317466 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care only
Number of subjects: 509
Study 7191299 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay g 5421 (acarbose)
Number of subjects: 10
Study 7191299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30907429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsi-lesional cerebellar rTMS (10 Hz, 250 pulses)
Number of subjects: 30
Study 30907429 — intervention group
Group type: EXPERIMENTAL
Intervention: Contra-lesional cerebellar rTMS (10 Hz, 250 pulses)
Number of subjects: 30
Study 30907429 — intervention group
Group type: COMPARATOR
Intervention: Sham cerebellar rTMS
Number of subjects: 30
Study 28513245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation
Number of subjects: 25
Study 28513245 — intervention group
Group type: COMPARATOR
Intervention: Seated desk
Number of subjects: 25
Study 26360086 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative-care depression care management (DCM) intervention
Number of subjects: 326
Study 26360086 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care as usual
Number of subjects: 326
Study 23572075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg/d, twice daily for 28 days)
Number of subjects: 40
Study 23572075 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 28 days)
Number of subjects: 40
Study 21980828 — intervention group
Group type: EXPERIMENTAL
Intervention: Suplatast tosilate (100 mg orally 3 times a day for 2 years)
Number of subjects: 32
Study 21980828 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (100 pg inhaled twice a day for 2 years)
Number of subjects: 32
Study 19212170 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TACE
Number of subjects: 108
Study 19212170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative treatment)
Number of subjects: 108
Study 16881779 — intervention group
Group type: EXPERIMENTAL
Intervention: Passage meditation intervention (8-week, 2-hr per week training)
Number of subjects: 58
Study 16881779 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 58
Study 16881779 — intervention group
Group type: EXPERIMENTAL
Intervention: Passage meditation intervention
Number of subjects: 58
Study 14604604 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 20
Study 10341400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuchal translucency measurements in fetuses affected by homozygous alpha-thalassemia-1
Number of subjects: 94
Study 10341400 — intervention group
Group type: COMPARATOR
Intervention: Nuchal translucency measurements in controls from the general obstetric population
Number of subjects: 94
Study 8983437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (DSCG) at concentrations of 10(‐7) ‐ 10(‐9M)
Number of subjects: 20
Study 8983437 — intervention group
Group type: COMPARATOR
Intervention: Control group (Healthy Subjects)
Number of subjects: 20
Study 8983437 — intervention group
Group type: COMPARATOR
Intervention: Control group (Seasonal Asthmatic)
Number of subjects: 20
Study 1827967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 30